Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction
- PMID: 24130003
- PMCID: PMC4545244
- DOI: 10.1161/CIRCHEARTFAILURE.113.000359
Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction
Abstract
Background: Despite the growing epidemic of heart failure with preserved ejection fraction (HFpEF), no valid measure of patients' health status (symptoms, function, and quality of life) exists. We evaluated the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated measure of HF with reduced EF, in patients with HFpEF.
Methods and results: Using a prospective HF registry, we dichotomized patients into HF with reduced EF (EF≤ 40) and HFpEF (EF≥50). The associations between New York Heart Association class, a commonly used criterion standard, and KCCQ Overall Summary and Total Symptom domains were evaluated using Spearman correlations and 2-way ANOVA with differences between patients with HF with reduced EF and HFpEF tested with interaction terms. Predictive validity of the KCCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalization. Covariate adjustment was made using Cox proportional hazards models. Internal reliability was assessed with Cronbach's α. Among 849 patients, 200 (24%) had HFpEF. KCCQ summary scores were strongly associated with New York Heart Association class in both patients with HFpEF (r=-0.62; P<0.001) and HF with reduced EF (r=-0.55; P=0.27 for interaction). One-year event-free rates by KCCQ category among patients with HFpEF were 0 to 25=13.8%, 26 to 50=59.1%, 51 to 75=73.8%, and 76 to 100=77.8% (log rank P<0.001), with no significant interaction by EF (P=0.37). The KCCQ domains demonstrated high internal consistency among patients with HFpEF (Cronbach's α=0.96 for overall summary and ≥0.69 in all subdomains).
Conclusions: Among patients with HFpEF, the KCCQ seems to be a valid and reliable measure of health status and offers excellent prognostic ability. Future studies should extend and replicate our findings, including the establishment of its responsiveness to clinical change.
Keywords: health status; heart failure, diastolic; quality of life.
Figures



Similar articles
-
Patient-reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence.ESC Heart Fail. 2020 Oct;7(5):2051-2062. doi: 10.1002/ehf2.12950. Epub 2020 Aug 30. ESC Heart Fail. 2020. PMID: 32862518 Free PMC article.
-
Comparing Measures to Assess Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction.JACC Heart Fail. 2018 Jul;6(7):552-560. doi: 10.1016/j.jchf.2018.02.006. Epub 2018 Jun 6. JACC Heart Fail. 2018. PMID: 29885952 Free PMC article.
-
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.JACC Heart Fail. 2019 Oct;7(10):862-874. doi: 10.1016/j.jchf.2019.05.015. Epub 2019 Jul 10. JACC Heart Fail. 2019. PMID: 31302043
-
Predictive value of quality of life as measured by KCCQ in heart failure patients: A meta-analysis.Eur J Clin Invest. 2024 Sep;54(9):e14233. doi: 10.1111/eci.14233. Epub 2024 Apr 26. Eur J Clin Invest. 2024. PMID: 38666585
-
Changes in health-related quality of life and treatment effects in chronic heart failure: a meta-analysis.Int J Cardiol. 2023 Sep 1;386:65-73. doi: 10.1016/j.ijcard.2023.05.032. Epub 2023 May 19. Int J Cardiol. 2023. PMID: 37211049
Cited by
-
Novel Trial Design: CHIEF-HF.Circ Heart Fail. 2021 Mar;14(3):e007767. doi: 10.1161/CIRCHEARTFAILURE.120.007767. Epub 2021 Mar 16. Circ Heart Fail. 2021. PMID: 33724883 Free PMC article.
-
Change of Health-Related Quality of Life Over Time and Its Association With Patient Outcomes in Patients With Heart Failure.J Am Heart Assoc. 2020 Sep;9(17):e017278. doi: 10.1161/JAHA.120.017278. Epub 2020 Aug 19. J Am Heart Assoc. 2020. PMID: 32812460 Free PMC article.
-
Defining changes in physical limitation from the patient perspective: insights from the VITALITY-HFpEF randomized trial.Eur J Heart Fail. 2022 May;24(5):843-850. doi: 10.1002/ejhf.2481. Epub 2022 Apr 3. Eur J Heart Fail. 2022. PMID: 35274420 Free PMC article. Clinical Trial.
-
Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study.Front Cardiovasc Med. 2023 Aug 29;10:1238843. doi: 10.3389/fcvm.2023.1238843. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37711563 Free PMC article.
-
Clinical Validation of Novel Digital Measures: Statistical Methods for Reliability Evaluation.Digit Biomark. 2023 Aug 9;7(1):74-91. doi: 10.1159/000531054. eCollection 2023 Jan-Dec. Digit Biomark. 2023. PMID: 37588480 Free PMC article. Review.
References
-
- Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. The New England journal of medicine. 2006;355:251–259. - PubMed
-
- Hogg K, McMurray J. The treatment of heart failure with preserved ejection fraction ("diastolic heart failure") Heart failure reviews. 2006;11:141–146. - PubMed
-
- Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. Journal of the American College of Cardiology. 2004;43:317–327. - PubMed
-
- Speight J, Barendse SM. Fda guidance on patient reported outcomes. Bmj. 2010;340:c2921. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous